New Small-Scale Expression Packages: RushMab™- Ready in just 8 days! LEARN MORE

Biointron Insights: Antibody Industry Report (Q1 2024 Insights, Trends & Analysis) LEARN MORE

Biointron - リコンビナント抗体発現/開発サービス

Antibody Antibody Antibody

カスタムサービス&プロダクト品

Why you should choose us

  • 先進的抗体ソリューション

    私たちは抗体の発現、開発、最適化に注力し、先進的な自動化生産ラインを持ち、競争力のある価格と効率的なリードタイムを提供できます。

  • ユニークな細胞株を商品化

    私たちはECACCからライセンスされたCHOK1BN細胞株の商業化に関する排他的な再ライセンス権を保有しています。

  • グローバルな協力体制

    私たちの1,500以上のグローバルなバイオテクノロジー企業や製薬企業とのパートナーシップになり、そして、国際的な臨床段階での共同の進歩と結びついています。

  • 信頼と所有権

    私たちは、お客様に提供した抗体の所有権を守り、機密情報の保持をお約束します。

Antibody

Biointronとの協力により、最適化された効率的で経済的かつ最高水準のカスタム抗体ソリューションを提供します。

About Biointron

Biointronは2012年に設立され、ISO 9001:2015認証を取得し、抗体の発見、開発、最適化分野のハイテク企業です。


Biointronは、リーディングな高スループットの再組み合わせ抗体/タンパク質発現および開発サービスプロバイダーです。遺伝子配列から抗体の精製まで、わずか2週間で行います。Biointronは、1500社以上のバイオテクノロジー企業や製薬企業に数万種類の再組み合わせ抗体を提供しています。

詳しくはこちら 詳しくはこちら

お客様からの声

Biointronのパートナーやクライアントから、Biointronの専門知識がもたらす変革のインパクトについて学びましょう。

"We evaluated the 6 proteins you produced for us and we were quite pleased by the results. our internal assessments of the molecules are very encouraging so we would like to potentially expand this further."

— AstraZeneca

"We have tested both batches of the antibodies you sent us. They're active and give comparable results with little batch to batch variation."

— AbbVie

"Excellent.The protein quality and activity was high and up to our standards, we appreciate the help and the work.The short timeline for the production is the main factor Biointron differs from other CROs."

— Moderna

"Great working with you, I've been highly impressed and recommending you to many in my network."

— Sanofi

"I just wanted to give you a quick heads-up regarding the expression we conducted at Biointron. Essentially, everything went well and was super fast, so we are all very much satisfied."

— Merck KGaA

"BioIntron was the best from the three: it was the only company that was able to express all the sequences and the yield for those proteins that the other two companies also could express was, generally, higher."

— ImmuVia, LLC

ニュース一覧

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

Apr 07, 2024
抗体業界の動向

Welcome back to Antibody Basics by Biointron, Part 6. In this episode, we’ll talk about Antibody-Drug Conjugates (ADCs), the drug type taking the biopharmaceutical industry by storm.What are antibody-drug conjugates (ADCs)?Composed of a monoclonal antibody (mAb) covalently bonded to a biologically

Apr 19, 2024
ブログ

​The AACR Annual Meeting 2024 was held in San Diego, CA from April 5-10, and featured the latest advancements in cancer research, with hundreds of poster presentations, lectures, and exhibits. Scientists, health care professionals, and industry experts from around the world gathered to share innovations and trends in oncology, including: Advances in Diagnostics and Therapeutics...

Apr 17, 2024
ブログ

In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#

Mar 23, 2024
ニュース

Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.

Mar 15, 2024
ニュース

Celebrate International Women's Day with Biointron's female workforce!

Mar 15, 2024
ニュース

Join Biointron at a fun sticker collection game during AACR 2024! Keep an eye on our social media! During this game period, Biointron will continue our daily social postings with Dr.Youngs hidden here and there! Take a screenshot every time you spot one, collect 25+ and win AirPods!

Mar 28, 2024
イベント

The Biointron team is excited to announce our participation in the Festival of Biologics 2024.

Dec 14, 2023
イベント

Biointron is thrilled to be part of the 4th Fc-Mediated Function Summit, a pivotal event focusing on the latest developments in FcRn, FcγR, and IgG, aiming to enhance related therapeutic applications. This unique conference, happening in Boston from April 16-18, 2024, will be gathering over 80 specialists in the field to share insights on molecular engineering and clinical outcomes.

Mar 20, 2024
イベント

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。